Navigation Links
Breast cancer: Reducing the risk of unnecessary chemo
Date:11/8/2010

This release is available in French.

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning. But studies show that for most patients with early stage breast cancer, chemotherapy following surgery is totally unnecessary and therefore does more harm than good.

Identifying whether a patient's cancer is at low or high risk of recurring would help doctors reduce unnecessary treatments for low risk patients. This could have a huge impact on a patient's quality of life and also significantly reduce the cost of health care.

Did you know?

Chemotherapy can be devastating both physically and emotionally. Side effects of breast cancer chemotherapy range from nausea, vomiting and hair loss to mouth sores, menopause, infertility, numbness and aching of the joints, hands and feet.

Currently, most doctors assess a patient's prognosis using their age and "tumour grade," but this approach doesn't work very well. Now, NRC researchers have developed a tool to determine which breast cancer patients have little risk of their disease recurring. The tool an algorithm that identifies "gene expression signatures" or biomarkers that can predict low risk tumours with 87-100 percent accuracy in different groups of patients has the potential to virtually eliminate unnecessary chemotherapy.

To conduct their study, which appeared in a recent issue of Nature Communications, Dr. Edwin Wang and his colleagues at the NRC Biotechnology Research Institute in Montreal (NRC-BRI) used published data on gene expression profiles from more than 1000 breast cancer samples. "Every tumour has a gene expression profile, which indicates how the patient's genes have changed," he explains. "We combined this data with information on the patient's outcome such as whether the original tumour spread and how long the person survived to develop our algorithm."

The NRC team now hopes to see its algorithm applied in a clinical setting. "We have a provisional patent on the intellectual property and we would like to get a Canadian company to license it and turn it into a kit format," says Dr. Maureen O'Connor of NRC-BRI, who co-authored the study. "We've had interest expressed from more than one company so far."

Dr. O'Connor adds that the NRC algorithm could be adapted to other types of cancer where over-treatment is common, such as prostate cancer. "Prostate cancer in particular is usually not an aggressive disease, but the treatment can be extreme," she says. "We would like to develop a test that can predict with 99 percent accuracy whether a patient's cancer is not aggressive, so they can make the best decision about whether to proceed with treatment right away."

In future, the algorithm may also help pave the way toward personalized therapy for cancer patients. "On average, every cancer patient has 14-16 mutated genes," says Dr. Wang. "Based on their unique genetic signature, we hope to figure out which mutations to target to block the cancer process in each patient."


'/>"/>

Contact: NRC Media Relations
media@nrc-cnrc.gc.ca
613-991-1431
National Research Council of Canada
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology: